News Agency
The Times

Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

  • Written by PR Newswire

SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer.

Based on 9MW2821's current ongoing monotherapy clinical data, in 20...

Read more: Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion